Rafferty Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Rafferty Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11,724	Closed	-$45K	–	1014
2020 Q1	$45K	Sell	11,724 -87,884	-88%	-$379K	﹤0.01%	578
2019 Q4	$507K	Sell	99,608 -29,792	-23%	-$158K	0.01%	686
2019 Q3	$654K	Sell	129,400 -54,289	-30%	-$271K	0.01%	614
2019 Q2	$1.13M	Sell	183,689 -12,328	-6%	-$59.4K	0.02%	540
2019 Q1	$910K	Buy	+196,017	New	+$887K	0.01%	568

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Rafferty Asset Management's PGNX Position: Q2 2020 in Review

Rafferty Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 11,724 shares — an estimated $45K sold.

Rafferty Asset Management first reported a position in PGNX in Q1 2019 and held it in 5 quarters. The position peaked at $1.13M in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Rafferty Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Rafferty Asset Management sold 11,724 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $45K.
Rafferty Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2019 and held it in 5 quarters.
Rafferty Asset Management's Progenics Pharmaceuticals Inc position peaked at $1.13M in Q2 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Rafferty Asset Management's 13F filing for Q2 2020, filed 7 Aug 2020.